Breaking News


Treatment of scalp psoriasis with adalimumab


A 16-week randomized controlled trial assessed the efficacy and safety of adalimumab as an adjunctive treatment with calcipotriol/betamethasone ointment (C/B) in 730 patients with scalp psoriasis. The dose of adalimumab was 80 mg at week 0 and 40 mg on alternate weeks for weeks 1-15. Topical C/B or vehicle was applied daily for 4 weeks then as necessary (but not to face, scalp or nails). The primary endpoint was the percentage of patients achieving a 75% or greater decrease from baseline in the Psoriasis Area and Severity Index 75 (PASI-75) at week 16. The Psoriasis Scalp Severity Index (PSSI) was assessed at baseline and at weeks 8 and 16. PASI-75 ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list